马拉韦罗抑制 EBV 蛋白激酶的 Epstein-Barr 病毒转录。
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.
机构信息
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
出版信息
J Virol. 2013 May;87(9):5311-5. doi: 10.1128/JVI.03505-12. Epub 2013 Feb 28.
Abstract
Maribavir (MBV) inhibits Epstein-Barr virus (EBV) replication and the enzymatic activity of the viral protein kinase BGLF4. MBV also inhibits expression of multiple EBV transcripts during EBV lytic infection. Here we demonstrate, with the use of a BGLF4 knockout virus, that effects of MBV on transcription take place primarily through inhibition of BGLF4. MBV inhibits viral genome copy numbers and infectivity to levels similar to and exceeding levels produced by BGLF4 knockout virus.
摘要
马拉韦罗（MBV）可抑制 EBV 复制和病毒蛋白激酶 BGLF4 的酶活性。MBV 还可抑制 EBV 裂解感染过程中多种 EBV 转录本的表达。本文通过 BGLF4 缺失病毒证实，MBV 对转录的作用主要通过抑制 BGLF4 实现。MBV 可将病毒基因组拷贝数和感染性抑制至与 BGLF4 缺失病毒相当或更高的水平。
相似文献
1
Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.马拉韦罗抑制 EBV 蛋白激酶的 Epstein-Barr 病毒转录。
J Virol. 2013 May;87(9):5311-5. doi: 10.1128/JVI.03505-12. Epub 2013 Feb 28.
2
Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.马里巴韦和选定的吲哚咔唑对爱泼斯坦-巴尔病毒蛋白激酶BGLF4及病毒裂解复制的影响。
Antimicrob Agents Chemother. 2004 May;48(5):1900-3. doi: 10.1128/AAC.48.5.1900-1903.2004.
3
Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.马里巴韦除了抑制病毒DNA复制外，还能抑制爱泼斯坦-巴尔病毒转录。
J Virol. 2009 Dec;83(23):12108-17. doi: 10.1128/JVI.01575-09. Epub 2009 Sep 16.
4
Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase.传染性病毒的高效产生需要爱泼斯坦-巴尔病毒蛋白激酶的酶活性。
Virology. 2009 Jun 20;389(1-2):75-81. doi: 10.1016/j.virol.2009.04.007. Epub 2009 May 8.
5
SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function.SUMO 结合由 Epstein-Barr 病毒蛋白激酶 BGLF4 介导，对 BGLF4 功能至关重要。
J Virol. 2012 May;86(10):5412-21. doi: 10.1128/JVI.00314-12. Epub 2012 Mar 7.
6
Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4.蛋白质芯片鉴定爱泼斯坦-巴尔病毒蛋白激酶BGLF4的底物
J Virol. 2009 May;83(10):5219-31. doi: 10.1128/JVI.02378-08. Epub 2009 Feb 25.
7
Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.爱泼斯坦-巴尔病毒（EBV）编码的蛋白激酶对EBV DNA聚合酶持续合成因子EA-D的磷酸化作用以及L-核糖核苷苯并咪唑1263W94的影响
J Virol. 2002 Feb;76(3):998-1003. doi: 10.1128/jvi.76.3.998-1003.2002.
8
BGLF4 kinase modulates the structure and transport preference of the nuclear pore complex to facilitate nuclear import of Epstein-Barr virus lytic proteins.BGLF4激酶调节核孔复合体的结构和转运偏好，以促进爱泼斯坦-巴尔病毒裂解蛋白的核输入。
J Virol. 2015 Feb;89(3):1703-18. doi: 10.1128/JVI.02880-14. Epub 2014 Nov 19.
9
Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.替诺福韦前药通过靶向病毒 DNA 聚合酶，强力抑制 Epstein-Barr 病毒裂解性 DNA 复制。
Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12368-12374. doi: 10.1073/pnas.2002392117. Epub 2020 May 14.
10
DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.在缺乏爱泼斯坦-巴尔病毒（EBV）裂解性DNA复制且对ZEBRA表达作出反应的情况下，DNA损伤信号被诱导。
PLoS One. 2015 May 7;10(5):e0126088. doi: 10.1371/journal.pone.0126088. eCollection 2015.
引用本文的文献
1
Association and Interaction of Epstein-Barr Virus with SARS-CoV-2 Infection-A Review.爱泼斯坦-巴尔病毒与严重急性呼吸综合征冠状病毒2感染的关联及相互作用——综述
Viruses. 2025 Jun 26;17(7):903. doi: 10.3390/v17070903.
2
Vaxtherapy, a Multiphase Therapeutic Protocol Approach for Longvax, the COVID-19 Vaccine-Induced Disease: Spike Persistence as the Core Culprit and Its Downstream Effects.疫苗疗法，一种针对新冠疫苗诱导疾病Longvax的多阶段治疗方案：刺突蛋白持续存在作为核心罪魁祸首及其下游影响
Diseases. 2025 Jun 30;13(7):204. doi: 10.3390/diseases13070204.
3
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.重新利用对爱泼斯坦-巴尔病毒有活性的已获许可药物治疗多发性硬化症：一种系统方法。
CNS Drugs. 2025 Mar;39(3):305-320. doi: 10.1007/s40263-024-01153-5. Epub 2025 Jan 10.
4
[Refractory or resistant cytomegalovirus infections after hematopoietic stem cell transplantation: diagnosis and management].造血干细胞移植后难治性或耐药性巨细胞病毒感染：诊断与管理
Zhonghua Xue Ye Xue Za Zhi. 2024 Nov 14;45(11):1058-1064. doi: 10.3760/cma.j.cn121090-20240615-00223.
5
EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes.异基因造血干细胞移植（HSCT）受者中 EBV 的再激活与疾病及其对 HSCT 结局的影响。
Viruses. 2024 Aug 14;16(8):1294. doi: 10.3390/v16081294.
6
Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.新型抗病毒药物来特莫韦和马瑞巴韦时代巨细胞病毒感染的管理
Infect Dis Rep. 2024 Jan 18;16(1):65-82. doi: 10.3390/idr16010005.
7
Prevalence, management, and new treatment modalities of EBV-DNA-emia and EBV-PTLD after allo-HCT: survey of Infectious Diseases Working Party EBMT.异基因造血干细胞移植后 EBV-DNA 血症和 EBV-PTLD 的流行情况、处理方法和新的治疗方式：EBMT 传染病工作组的调查。
Bone Marrow Transplant. 2024 Jan;59(1):59-65. doi: 10.1038/s41409-023-02129-7. Epub 2023 Oct 23.
8
Maribavir.马里巴韦
Hosp Pharm. 2023 Aug;58(4):336-344. doi: 10.1177/00185787221101480. Epub 2022 Dec 21.
9
Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study.靶向 Epstein-Barr 病毒相关疾病的信号通路：机制、调控及临床研究。
Signal Transduct Target Ther. 2021 Jan 12;6(1):15. doi: 10.1038/s41392-020-00376-4.
10
A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.一种基于机制的靶向筛选方法，用于鉴定 Epstein-Barr 病毒导向的抗病毒药物。
J Virol. 2020 Oct 14;94(21). doi: 10.1128/JVI.01179-20.
本文引用的文献
1
Progress in the development of new therapies for herpesvirus infections.疱疹病毒感染新疗法的研究进展。
Curr Opin Virol. 2011 Dec;1(6):548-54. doi: 10.1016/j.coviro.2011.10.015.
2
Benzimidazole analogs inhibit human herpesvirus 6.苯并咪唑类似物抑制人类疱疹病毒 6。
Antimicrob Agents Chemother. 2011 May;55(5):2442-5. doi: 10.1128/AAC.01523-10. Epub 2011 Feb 7.
3
Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.马里巴韦除了抑制病毒DNA复制外，还能抑制爱泼斯坦-巴尔病毒转录。
J Virol. 2009 Dec;83(23):12108-17. doi: 10.1128/JVI.01575-09. Epub 2009 Sep 16.
4
Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir.人巨细胞病毒UL97激酶在病毒感染中的作用及其受马里巴韦的抑制作用
Rev Med Virol. 2009 Jul;19(4):215-29. doi: 10.1002/rmv.615.
5
Efficient production of infectious viruses requires enzymatic activity of Epstein-Barr virus protein kinase.传染性病毒的高效产生需要爱泼斯坦-巴尔病毒蛋白激酶的酶活性。
Virology. 2009 Jun 20;389(1-2):75-81. doi: 10.1016/j.virol.2009.04.007. Epub 2009 May 8.
6
Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4.蛋白质芯片鉴定爱泼斯坦-巴尔病毒蛋白激酶BGLF4的底物
J Virol. 2009 May;83(10):5219-31. doi: 10.1128/JVI.02378-08. Epub 2009 Feb 25.
7
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study.马立巴韦预防异基因干细胞移植受者巨细胞病毒感染：一项多中心、随机、双盲、安慰剂对照、剂量范围研究。
Blood. 2008 Jun 1;111(11):5403-10. doi: 10.1182/blood-2007-11-121558. Epub 2008 Feb 19.
8
Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.爱泼斯坦-巴尔病毒编码的蛋白激酶（BGLF4）参与传染性病毒的产生。
J Virol. 2007 May;81(10):5407-12. doi: 10.1128/JVI.02398-06. Epub 2007 Mar 14.
9
Antiviral drugs for cytomegalovirus diseases.用于巨细胞病毒疾病的抗病毒药物。
Antiviral Res. 2006 Sep;71(2-3):154-63. doi: 10.1016/j.antiviral.2006.05.002. Epub 2006 May 23.
10
Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides.假定的人巨细胞病毒门户蛋白pUL104与大末端酶亚基pUL56的相互作用及其被苯并咪唑-D-核糖核苷抑制的作用
J Virol. 2005 Dec;79(23):14660-7. doi: 10.1128/JVI.79.23.14660-14667.2005.
Zotero 插件